Management of diabetic and hypertensive cardiovascular disease

Current Hypertension Reports

Volumn 5, Issue 4, 2003, Pages 309-315

  Frohlich, Edward D ^a   Sowers, James R ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONIDINE; DOXAZOSIN; IRBESARTAN; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TERAZOSIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR;

CARDIOVASCULAR DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; EVIDENCE BASED MEDICINE; HIGH POTASSIUM INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOKALEMIA; INSULIN RESISTANCE; KINESIOTHERAPY; LOW DRUG DOSE; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SODIUM RESTRICTION; TARGET ORGAN; TREATMENT OUTCOME; WEIGHT GAIN; DIABETIC ANGIOPATHY; DRUG ANTAGONISM; HYPERTENSION;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIURETICS; HUMANS; HYPERTENSION; RECEPTORS, ANGIOTENSIN;

EID: 0642284448     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-003-0039-4     Document Type: Review

References (50)

1. Executive Summary of the Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Reviewer for National High Blood Pressure Education Program Coordinating Committee. Arch Intern Med 1998, 158:1855-1867.
2. National Cholesterol Education Program Coordinating Committee: Third Report of the National Cholesterol Education Program on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 2002, 106:3143-3421.
3. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The Sixth Report of the joint National Committee (JNC-VI) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997, 157:2413-2446.
4. 9 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999, 17:151-183.
5. Sacks FM, Svetkey LP, Vollmer WM, et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet: DASH-Sodium Collaborative Research Group. N Engl J Med 2001, 344:3-10.
6. Obarzanek E, Sacks FM, Vollmer WM, et al., for the DASH Research Group. Effects on blood lipids of a blood pressure lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001, 74:80-89.
7. Frohlich ED: Hemodynamic factors in the pathogenesis and maintenance of hypertension. Fed Proceed 1982, 41:2400-2408.
8. Frohlich ED, Apstein C, Chobanian AV, et al.: The heart in hypertension. N Engl J Med 1992, 327:998-1008.
9. Frohlich ED: Local hemodynamic changes in hypertension: Therapeutic implications for preservation of target organs. Hypertension 2001, 38:1388-1394.
10. Nunez, E, Hosoya K, Susic D, Frohlich ED: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997, 29:519-524.
11. Susic D, Varagic J, Frohlich ED: Abnormal renal vascular responses to dipyridamole-induced vasodilation in spontaneously hypertensive rats. Hypertension 2001, 37:894-897.
12. Frohlich ED: Risk mechanisms in hypertensive heart disease. Hypertension 1999, 34:782-789.
13. Sowers JR, Haffner S: Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002, 40:781-788.
14. Frohlich ED: Obesity and hypertension: Hemodynamic aspects. Ann Epidemiol 1991, 1:287-293.
15. Grossman E, Shemesh J, Shamiss A, et al.: Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992, 152:1001-1004.
16. Ono Y, Ono H, Matsuoka H, et al.: Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 1999, 34:609-616.
17. Ono H, Ono Y, Takanohashi A, et al.: Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in SHR. Hypertension 2001, 38:1300-1306.
18. Schiffren EL: Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002, 112:409-418.
19. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The tale of hemodynamically mediated glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982, 307:652-659.
20. Frohlich ED, Arthur C: Corcoran Memorial Lecture: Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997, 29:188-193.
21. Fagan TC, Sowers JR: Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. Arch Intern Med 1999, 159:1033-1034.
22. Haffner SM: Coronary heart disease inpatients with diabetes. N Engl J Med 2000, 342:1040-1042.
23. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
24. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
25. Rodriguez BL, Lau N, Burchfiel CM, et al.: Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999, 22:1262-1265.
26. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
27. Coronary heart disease risk assessment in diabetes mellitus: a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 2001, 18:355-359.
28. Assman G, Cullen P, Schulte H: Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002, 105:310-315.
29. Grundy SM, Benjamin IJ, Burke GL, et al.: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100:1134-1146.
30. Bakris GL, Williams M, Dworkin L, et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committee Working Group. Am J Kidney Dis 2000, 36:646-661.
31. American Diabetes Association: Treatment of hypertension in adults with diabetes. Diabetes Care 2002, 25(Suppl 1):571-573.
32. Sowers JR, Reed J: Clinical advisory treatment of hypertension and diabetes. J Clin Hypertens 2000 1999, 2:132-133.
33. Tuomilehto J, Lindstrom J, Eriksson JG, et al., for Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in leftstyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
34. McFarlane SI, Jacober SJ, Winer N, et al.: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical center. Diabetes Care 2000, 25:718-723.
35. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
36. Curb JD, Pressil MS, Cutler JA, et al.: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated hypertension. JAMA 1996, 276:1886-1892.
37. Wing LMH: A comparison of outcomes with ACE inhibitors and diuretics in the elderly. N Engl J Med 2003, 348:In press.
38. Frohlich ED: Treating hypertension - what are we to believe? N Engl J Med 2003, 245:639-640.
39. Remuzzi G, Schieppati A, Ruggenenti P: Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
40. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.
41. Sowers JR, Bakris GL: Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 2000, 342:969-970.
42. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and morality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004-1010.
43. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
44. Parving HH, Lehnert H, Brocner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
45. Lewis EJ, Hunsicker LG, Clark WR, et al.: Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
46. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group. BMJ 1998, 317:703-713.
47. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-1228.
48. Hanson L, Zanchetti A, Carruthers SG, et al., for the HOT study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998, 351:17155-17162.
49. Tuomilehto J, Rastenyto D, Birkenhager WH, et al., for the Systolic Hypertension in Europe Trial Investigators: Effects of calcium channel blockers in older patients with diabetes and systolic hypertension. N Engl J Med 1999, 340:677-684.
50. McFarlane S, Sowers JR: Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab 2003, 88:516-523.